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Abstract 
Background: Drug development is currently hampered by high attrition rates; many developed treatments fail 
during clinical testing. Part of the attrition may be due to low animal‑to‑human translational success rates; so‑called 
“translational failure”. As far as we know, no systematic overview of published translational success rates exists.
Systematic scoping review: The following research question was examined: “What is the observed range of the 
animal‑to‑human translational success (and failure) rates within the currently available empirical evidence?”. We 
searched PubMed and Embase on 16 October 2017. We included reviews and all other types of “umbrella”‑studies of 
meta‑data quantitatively comparing the translational results of studies including at least two species with one being 
human. We supplemented our database searches with additional strategies. All abstracts and full‑text papers were 
screened by two independent reviewers. Our scoping review comprises 121 references, with various units of meas‑
urement: compound or intervention (k = 104), study/experiment (k = 10), and symptom or event (k = 7). Diagnostic 
statistics corresponded with binary and continuous definitions of successful translation. Binary definitions comprise 
percentages below twofold error, percentages accurately predicted, and predictive values. Quantitative definitions 
comprise correlation/regression  (r2) and meta‑analyses (percentage overlap of 95% confidence intervals). Translational 
success rates ranged from 0 to 100%.
Conclusion: The wide range of translational success rates observed in our study might indicate that translational 
success is unpredictable; i.e. it might be unclear upfront if the results of primary animal studies will contribute to 
translational knowledge. However, the risk of bias of the included studies was high, and much of the included evi‑
dence is old, while newer models have become available. Therefore, the reliability of the cumulative evidence from 
current papers on this topic is insufficient. Further in‑depth “umbrella”‑studies of translational success rates are still 
warranted. These are needed to evaluate the probabilistic evidence for predictivity of animal studies for the human 
situation more reliably, and to determine which factors affect this process.
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Background
The general aim of biomedical research is to develop pos-
sible cures for diseases. Current drug development is 
handicapped by high attrition rates; many molecules that 
were promising during preclinical development fail dur-
ing subsequent clinical testing [1]. At the moment, return 
on investment in pharma is lower than ever [2]. Part of 
the attrition may be due to low animal-to-human trans-
lational success rates; the so-called “translational failure” 
[3].
There are two fundamental perspectives potentially 
explaining translational failures. The first main perspec-
tive is that the concept of animal-to-human predictability 
is fundamentally mistaken [4]. This perspective is based 
on the observation that the hypothesis that animals are 
predictable for humans has never been scientifically 
tested [5, 6], and that there are important differences 
between species in e.g. physiology, genetics, epigenetics 
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and molecular biology [4, 7]. Animal studies have his-
torically been implemented in drug approval procedures, 
which may have been based on scientifically outdated 
principles [8]. Besides, animals and humans are com-
plex systems, that are more than the sum of their parts, 
and therefore always unpredictable [9, 10]. From this 
perspective, animal experiments that are performed to 
inform human health are not ethically acceptable.
The second main perspective is that biomedical and 
pharmaceutical research advanced over the last decades 
because animal experiments are in general able to predict 
the situation in humans [11]. In this perspective, recent 
translational failure could be explained by suboptimal 
experimental design [12, 13], and lack of reproducibility 
in general [1]. Many of the factors involved in suboptimal 
design of animal studies and the resulting bias, have been 
reviewed before, and are increasingly taken into account 
by the scientific community [14–19].
Both perspectives are currently promoted by different 
groups of scientists. Neither group routinely refers to the 
total body of available evidence on animal-to-human pre-
dictability. This predictability, i.e. the translational suc-
cess rates, can be determined quantitatively in various 
manners. For example, researchers can sample clinical 
trials from a registry, retrieve the supporting preclini-
cal data and analyse to what extent the data correspond. 
Alternatively, they can sample preclinical studies with 
relevance to humans, and analyse subsequent clinical 
studies. Moreover, researchers can analyse the effects of a 
set of interventions (e.g. drugs) on specific outcomes (e.g. 
biochemistry, physiology and adverse events) in multiple 
species.
Several methods have been used to analyse transla-
tional success, and many authors have addressed the 
problem of attrition in translational research, e.g. [3, 
16, 20]. Most of the papers published on the topic pro-
vide expert opinions, narrative reviews or primary stud-
ies showing mechanistic similarities between species. As 
far as we know, no proper overview of the actual data is 
currently available. While the debate will not be decided 
by these data alone, an overview of the observed predic-
tive values in different data sets will aid the ethical dis-
course on the acceptability of those animal experiments 
intended to inform decisions for human exposure.
In medicine, systematic reviews (SRs) have long been 
considered to provide the highest level of research evi-
dence, as they combine all available data [21]. In animal 
research, SRs are increasingly used to collate all available 
evidence on a subject using transparent and reproduc-
ible methodology. We set out to summarise all available 
published evidence on animal to human translational 
success. Due to the lack of specific and sensitive indexing 
of this type of studies, performing a full comprehensive 
search to retrieve all available studies was not viable. We 
thus performed a systematic scoping review. Scoping 
reviews aim to estimate the size and quality of literature 
on a topic [22]. In the present systematic scoping review, 
we fully analysed the included papers, to summarise 
quantitative data from studies that assessed animal-to-
human translational success rates.
The main question was “What is the observed range of 
the animal-to-human translational success (and failure) 
rates within the currently available empirical evidence?” 
In contrast to a full systematic review, our review did 
not follow the PICO format for outcome measures as we 
included all relevant outcomes, and it did not comprise 
a full comprehensive systematic search. The search was 
supplemented by alternative strategies, as detailed in 
“Methods” section.
Besides studies explicitly addressing translational suc-
cess rates, we included meta-analyses comprising both 
human and animal data, and studies analysing the corre-
lation of similar outcomes between animals and humans, 
as they provide quantitative information on translation 
for individual interventions. As far as we are aware, we 
are the first to provide a systematic scoping review of all 
types of published findings (i.e. literature reviews and 
other types of “umbrella”-studies) on quantitative analy-
ses of animal-to-human translational success.
Methods
The protocol for this systematic scoping review was 
posted online on the SYRCLE website (http://www.
SYRCL E.nl) on 27 December 2017 [23], after performing 
the Pubmed and Embase searches, but before the start of 
paper selection.
Research question
The main research question for this systematic scoping 
review was: “What is the observed range of the animal-
to-human translational success (and failure) rates within 
the currently available empirical evidence?”. We originally 
defined translational success as “replication in a rand-
omized trial in humans of statistically significant positive, 
negative or neutral results for the primary study outcome 
in animal experiments”, and consequently, translational 
failure as not replicating the results of animal experi-
ments in a randomized trial for the primary study out-
come. We did not expect to find clinical trial publications 
after animal experiments with negative or neutral effi-
cacy results, nor did we expect to find many after positive 
toxicology results.
We intended to preferentially address studies on phase 
I–II trials to focus on early clinical trials over market 
access, as successful early trials do not always result 
in clinically available medication for reasons beyond 
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animal-to-human predictability. In practice, only few of 
the included references detailed the types of trials and 
experiments, or the primary study outcomes. During the 
screening of the retrieved references, these two elements 
thus had to be disregarded. Our working definition of 
translation therefore became “the quantitative degree 
of correspondence between the results from a trial in 
humans with results in animal experiments”. This was 
communicated between the screeners. We did not post 
an amendment to the protocol because we did not expect 
this broader definition to increase bias in the selection of 
studies and thereby the results.
Search
Our search consisted of 3 elements: animal models, 
human trials, and translation. We first tested several tra-
ditional comprehensive search strategies based on both 
medical subject headings (MeSH) and on words in the 
title, abstract and keywords in PubMed. Regardless of the 
exact combination of search terms used, the number of 
references retrieved became too high to manage within 
the timeframe of this project. We thus went for a less 
conventional scoping strategy, searching for MeSH-terms 
and title words only. As we expected to miss relevant lit-
erature this way, we introduced additional search strate-
gies (detailed below).
Our final search for Pubmed consisted of MeSH-terms 
and title words (including several synonyms) for animal 
models, human clinical trials and translation, combined 
with “AND”. We built an equivalent search for Embase 
(replacing MeSH terms with the corresponding Emtree 
terms), also including key words. We filtered for (sys-
tematic and other) reviews, letters and editorials. The 
full search strategy can be found in our protocol [23]. We 
performed our systematic scoping search in Pubmed and 
Embase on 16 October 2017.
Additional search strategies
Besides formal literature searches, we retrieved relevant 
references via two more routes. The first was screening 
of the reference lists of all included references and rel-
evant reviews. This is a standard approach in systematic 
reviews. The second alternative route was contacting 
experts in the field for additional references. Experts 
were (1) the authors; (2) their (direct and indirect) col-
leagues known to be interested in translational success, 
and (3) the first and last authors of all papers included 
from the search. Experts were contacted via email; a 
single reminder was sent after 1–2 weeks if they did not 
respond.
Selection of papers
We included studies and reviews quantitatively compar-
ing the results of studies including at least 2 species with 
one being human. We thus excluded studies and reviews 
comparing 2 non-human species or comparing outcomes 
between human clinical trials. There were no restrictions 
for language or publication date. All titles and abstracts 
retrieved from the search were independently screened 
by two reviewers. Full-text screening of the included 
papers was again performed by two independent review-
ers. Discrepancies were resolved by discussion between 
reviewers.
During the selection process, we came across several 
correlational studies of pharmacokinetic–pharmacody-
namic (PKPD) parameters after the administration of 
various molecules. While these papers do not describe 
translational success rates according to our original 
binary definition (replication of positive, negative or 
neutral results), they do provide continuous quantitative 
information on animal-to-human translation. As this is in 
line with our intended goal, we did include these papers. 
The same argumentation led to the inclusion of meta-
analyses in which both human and animal studies were 
compared as subgroups within a single meta-analysis.
Comparisons of outcome measures without an inter-
vention were excluded (e.g. [24–26]), as well as papers 
describing the effects of experimental design param-
eters on outcomes in several species (e.g. [27]. Ex  vivo 
and in vitro animal studies were also excluded (e.g. [28, 
29], as well as animal studies combining the animal with 
other (mostly in  vitro) data to improve predictive accu-
racy [30]. We only included studies that provided quan-
titative information on translational success (or failure); 
i.e. we excluded papers comparing a single human with 
a single animal study. The unit of analysis could vary, but 
included studies had to compare a specific set of com-
pounds/interventions, studies/experiments, or symp-
toms/events between species. The important work of 
O’Collins et  al. [31] was excluded from our analyses as 
their efficacy comparison between species is not based 
on the same set of drugs.
Besides, several important reviews focusing on trans-
lation from the animal study perspective only were 
excluded (e.g. [32–36]), as well as studies analysing how 
often animal studies were cited [37]. Further excluded 
were important papers on attrition rates and transla-
tion with a wider scope than animal-to-human transla-
tion (e.g. [3, 38–46]), papers presenting relevant graphs 
without informing us on summary values (e.g. [5], and 
quantitative studies on related phenomena such as mar-
ket withdrawal of drugs [47] and animal harm–human 
benefit analyses [48].
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Selection of data
When a single paper described multiple studies on dif-
ferent datasets, those compliant with our inclusion cri-
teria were included into the analyses separately. E.g. [49] 
described 3 studies of which 2 are included in this review; 
the 3rd study, on intestinal expression levels of transport-
ers and metabolic enzymes in rats and humans, did not 
comprise an intervention and was thus excluded.
If species were analysed separately, we included the 
separate data. If multiple analyses with the same outcome 
measure were based on the same data, we included the 
one with the largest sample size (which was deemed the 
most reliable), or, in a minority of studies with equal sam-
ple sizes, the most predictive one (i.e. the highest transla-
tional success rate). Including the most predictive results 
may have biased our results somewhat towards inflated 
translational success rates. For PKPD studies report-
ing ≥ 3 parameters, we preferentially selected the volume 
of distribution, the clearance and the half time, as these 
were most frequently reported.
For papers describing several meta-analyses based on 
the same studies, the primary outcomes were selected. 
If no primary outcome was described, again, the largest 
analyses were preferentially selected. If multiple binary 
analyses were based on the same data, we preferentially 
included the accuracy (see Table 1). If negative and posi-
tive predictive value (see Table  1) were both provided 
without the crude data (from which we could have calcu-
lated the accuracy), we included both values.
Analyses of translational success rates
As we observed a large range of reported translational 
success rates, we exploratively analysed the data further. 
However, different papers used different strategies for 
quantifying translation. It is important to realise that dif-
ferent definitions for translational success result in dif-
ferent diagnostic statistics, which may result in different 
values for the same data.
Different diagnostic statistics lead to different predic-
tive values, even when based on the same data, which we 
included as described in the preceding section. The dif-
ferences are clear for e.g. the percentage < twofold error 
versus the correlation [50], and for the sensitivity, speci-
ficity, positive predictive value and negative predictive 
value [51]. The data are not always so discrepant. For 
example, the percentage of overall correct predictions 
reported by Litchfield is 74% when both rat and dog are 
considered [52]. We can also use his data to calculate 
specificity (72%), sensitivity (76%), positive predictive 
value (68%), and negative predictive value (79%).
The diagnostic statistics can be clustered into two main 
categories: continuous (degree of comparability in effect 
size; e.g. correlation or  % overlap in confidence interval) 
and binary (translation yes/no; e.g. percentage accurately 
predicted or percentage below twofold error). For a direct 
comparison of continuous outcomes, analyses of correla-
tion and regression were common. For yes/no type deci-
sions, several binary classification measures were used, as 
described in Table 1.
Besides various analyses resulting in different values, 
different types of values for translational success have dif-
ferent meanings. For example, when analysing percent-
ages of binary success/failure rates, 50% is equivalent to 
tossing a coin, while 50% overlap in a confidence interval 
(meta-analyses), or 50% explained variance (correlation 
and regression) can be considered to result in meaning-
ful data.
If the authors of a paper did not provide a summary 
measure for translation, we calculated one where we 
could. For example, for a study on the predictive validity 
of pain models [53] we calculated the correlation coeffi-
cient for the maximum plasma concentration at the mini-
mum effective dose in rats and the maintenance dose in 
humans using Excel. When different sources were pro-
vided describing different values for a single data point 
(e.g. different values for a single drug in a correlational 
analysis), we used the median.
All included studies were tabulated. In our tabulations 
of study outcomes, we aimed to summarise the data and 
reflect the original authors’ view. To summarise our find-
ings quantitatively, we expressed all values for translation 
as percentages. The conversions are described in Table 2. 
For correlations and regression analyses, we selected  r2 
over r, as this value reflects the percentage of explained 
variation. When both correlation and % < twofold error 
were presented, we selected  r2 for inclusion in the analy-
ses as these values better reflect the actual data. Similarly, 
when binary classifications were provided, we preferen-
tially selected accuracy, or, when accuracy was not given, 
Table 1 Diagnostic statistics with  binary definitions 
of translational success. Adapted from e.g. [8]
AN animal negative, AP animal positive, FN false negative, FP false positive, HN 
human negative, HP human positive, TN true negative, TP true positive
Human test
Positive (HP) Negative (HN)
Animal test
 Positive (AP) TP FP
 Negative (AN) FN TN
Sensitivity = TP/HP
Specificity = TN/HN
Positive predictive value (PPV) = TP/AP
Negative predictive value (NPV) = TN/AN
Accuracy = (TP + TN)/(TP + FP + FN + TN)
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the positive and negative predictive values. For meta-
analyses, we determined the degree of overlap of the ani-
mal 95% confidence interval (CI) with the human 95% 
CI. There was only one study where the 95% CIs did not 
overlap, and in that study, the direction of the effect was 
opposite in animals compared to humans, included in the 
analyses as 0% translational success.
To visualise the variation in reported translational suc-
cess rates, we plotted all values from all included stud-
ies in a histogram. We then created boxplots with the 
individual data points in overlay. Plots were created in R 
version 3.5.0—“Joy in Playing” [54], using the GGPlot2 
package [55].
Risk of bias and reporting quality
According to the protocol, we analysed risk of bias and 
reporting quality of the included references for the fol-
lowing items: power calculation for the translational 
comparison, sampling method of the studies included in 
the analysis, type of data analysis, blinding in the sam-
pling procedure, blinding of the data analyst, control for 
publication bias (i.e. did the authors analyse the effect of 
potential underreporting of small neutral studies in their 
estimate of the translational success outcome), risk of 
bias analysis performed for each of the included studies, 
and overall risk of bias estimate. For each of these items, 
we separately analysed if they were reported, and if there 
were resulting risks of bias (yes/no/unclear). Of note, 
power analyses are not common in literature reviews, as 
systematic reviews aim to include all available evidence, 
and with complete sampling, power calculations become 
irrelevant.
Besides, as the included papers described some type 
of review of the literature, we analysed their compli-
ance with the PRISMA (Preferred Reporting Items for 
Systematic reviews and Meta-Analyses) guidelines for 
the following items (being aware that these guidelines 
do not necessarily apply to other review types): registra-
tion of a protocol, explicit description of eligibility crite-
ria, the number of screeners determining which papers 
to include, the number of scientists performing the 
data-extraction, whether an analysis of risk of bias was 
performed on the included studies individually and over-
all, if the analyses had been prespecified, if the limita-
tions of the review were discussed, and if the funding was 
described. At the time we posted our protocol, the more 
relevant PRISMA extension for scoping reviews [56] had 
not yet been published.
For funding, we further estimated whether there was a 
potential risk of funding bias, which could go either way. 
We scored a high risk of funding bias if the funder was 
indicated as or if any of the authors worked for a non-
governmental (animal rights) organisation, a pharmaceu-
tical company, or a governmental regulating agency (e.g. 
EMA, FDA).
Only those relevant PRISMA items not otherwise 
analysed were extracted. E.g. item 13 and 14 (summary 
measures and synthesis of results) overlap with our 
extracted data on type of analysis, and e.g. items 1 and 
2 (title and summary) were not deemed relevant for the 
overview provided in this paper. The item publication 
bias can be considered irrelevant for certain types of 
review, for example when internal databases are used. 
Where included references were not based on publica-
tions, we reinterpreted this item for the type of data 
included, e.g. the risk of studies not ending up in the 
internal database from which a dataset was extracted.
Results
Search and selection
Our search in PubMed retrieved 2486 references, that 
in EmBase retrieved 484. After duplicate removal, 2649 
references remained, after title-abstract screening, 287. 
After full-text screening, 26 references were included 
in this review. Screening the reference lists resulted in 
60 additional references. Contacting the first and last 
authors of the 26 references included from the search 
combined with contacting people in our network 
resulted in 35 additional references. The flow of papers 
is shown in Fig. 1.
Table 2 Measures used to reflect translational success rate
95% CI 95% confidence interval, PPV positive predictive value, NPV negative predictive value
Type of analysis Type of definition for translation Used value for % translational success
Correlation Continuous Squared correlation coefficient  (r2) expressed as percentage
Regression Continuous Squared correlation coefficient  (r2) expressed as percentage
Fold error Binary Percentage below twofold error
Meta‑analysis Continuous Percentage overlap of 95% CIs
Binary analyses Binary % accurate or PPV or NPV
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Characteristics of the included papers
Of the 121 included references, 119 were in English, 
one was in German, and one was in French. The unit 
of measurement was compound or other type of inter-
vention for 104 references, study/experiment for 10, 
and symptom or event for 7. The number of included 
interventions, studies or symptoms per reference 
ranged from 5 to 1256 (also see Fig. 8). Specific animal 
models were described in 35 references, and comprised 
e.g. xenografts, bile duct cannulated animals, chimeric 
mice, or a combination of various models.
Reporting information was limited; less than 15 ref-
erences reported sex, age or disease status of the ani-
mals or humans included in the analyses and the type 
of studies or trials. Information on dose was reported 
in 24 references, information on route of administra-
tion in 40 (mainly multiple and intravenous, also oral, 
intraperitoneal and topical). These data were not fur-
ther analysed.
Studies addressing translational success rates
Studies addressing general medical sciences and efficacy
Of the 121 included references, 16 addressed efficacy or 
translation in general. The results from these references 
are summarised in Table  3. Several of these references 
were familiar to the authors before starting this work and 
provided the background for our protocol [57–59]. Lindl 
et al. followed the results from 51 animal ethics requests, 
and found very little translation to the clinical situa-
tion [58], with their analysis restricted to a 10-year time 
window. This may be rather short for analysing transla-
tional success, as the development of new treatments is 
a lengthy process, (see e.g. [39]) and development times 
seem to increase over time [2]. Hackam et  al. followed 
highly cited animal studies, and found that about one-
third translated to randomised clinical trials [57]. Perel 
et  al. compared the effects of 6 interventions between 
animals and humans with systematic literature reviews, 
with half of them concordant [59]. We hoped to retrieve 
a number of comparable references, but only found one; 
Contopoulos-Ioannidis et  al. analysed 101 articles that 
described novel therapeutic or preventive promises 
based on animal data [60]. 16 of these novel interventions 
were tested in clinical trials, of which 12 had a positive 
result in the trial.
Three references compared the number of positive-
outcome studies between animals and humans for simi-
lar interventions [61–63]. Four other included references 
comprised meta-analyses showing both human and ani-
mal data [64–67].
The included analyses comprise correlational analy-
ses  (R2), the Chi-square test, relative risk, accuracy and 
meta-analyses.
Studies analysing adverse events and toxicology
Of the 121 included references, 28 addressed transla-
tion of safety studies. Adverse events were analysed in 
17 of these, carcinogenicity in 6. The other 5 references 
described translation for drug-induced liver injury, QT 
prolongation, skin sensitization, teratogenicity and toxic 
dose. The included references comprise analyses of con-
cordance, likelihood ratios, positive and negative predic-
tive values, sensitivity, Chi-square and correlation. The 
results from these references are summarised in Table 4.
Of note, the 4 references (comprising 6 studies) with 
sample sizes over 200 all fall within this category [68–71]. 
Tamaki et  al. studied 1256 adverse drug reactions after 
administration of 142 drugs that were approved in Japan 
from 2001 to 2010 [71]. 48% of the adverse drug reac-
tions could be predicted from the animal data. Fourches 
et al. mined the literature to create a data set of 951 com-
pounds with effects in the liver in different species [69]. 
The concordance of liver effects between animals and 
humans was relatively low. Olson et  al. described 221 
human toxicity events after administration of 150 (coded) 
compounds, as reported by 12 pharmaceutical companies 
[70]. The concordance rates between animal and human 
toxicity were 71% when all species were considered, with 
2486 references 
from Pubmed
35 references 
from networking
2649 references for title-
abstract  screening 
60 references from 
reference lists
121 references included 
in final review
484 references from 
EmBase
321 Duplicates 
removed
26 references  
from search
287 references for full-
text screening 
2362 Excluded
245 Excluded
Fig. 1 Flow scheme of papers
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nonrodents alone predictive for 63% and rodents for 43% 
of the events. Alden et al. reviewed drug labels from the 
physicians’ desk reference, which they searched for any 
mention of terms related to carcinogenesis [68]. This 
resulted in 533 active pharmaceutical ingredients that 
were further analysed. Of these, 287 had been tested in 
rodents, in which 161 tested positive for carcinogenicity. 
The authors presented the sensitivity (73%), positive pre-
dictive value (20%, refer to Table 1 for an explanation of 
predictive values; true positives are in this case ingredi-
ents that show carcinogenicity in animals and humans), 
negative predictive value (90%) and crude data.
Studies addressing pharmacokinetics
Of the 121 included references, 77 addressed transla-
tion of various pharmacokinetic (PK) parameters, mainly 
clearance, bioavailability, volume of distribution and con-
centration–time profiles. The results from these refer-
ences are summarised in Table 5. Besides animal–human 
correlations for PK values from several drugs, these stud-
ies often analyse the fold-error of the predicted compared 
to the observed value, and the percentage of compounds 
with a predicted value within twofold of the observed 
value.
Several scatterplots of pharmacokinetic parameters for 
a set of drugs in animals versus humans show low cor-
respondence rates, i.e. they do not show an apparent rela-
tionship between animal and human data (e.g. [72, 73]. 
Of note, these types of plots are specifically sensitive to 
selection bias; if one is familiar with the literature it is 
relatively easy to (consciously or subconsciously) select 
a set of drugs with relatively high or relatively low cor-
respondence. Besides, PK correlational review papers are 
often based on the same experiments and data; the same 
data have e.g. been included in [74–76].
Hypotheses‑generating analyses of translational success 
rates
The range of published translational success rates is 0% to 
100%. A histogram of all published translational success 
rates is provided in Fig. 2.
As we included outcomes from different types of 
analyses, we compared the effect of the two broadly 
defined definitions of translation; binary (translation 
successful yes/no) and continuous (amount of corre-
spondence; explained variance) in a boxplot (Fig.  3). 
For studies using binary definitions of translation, 
Table 3 References on translational success in general and in efficacy studies
K the number of included studies
Study ID Field of research Summary of findings
Briassoulis_2014 Sepsis Animal studies show clear protective effects of HSP72 in sepsis, human studies are inconclusive
Brossi_2015 Orthopedia Equine studies on the efficacy of platelet rich plasma (k = 63) mostly show positive results, human 
studies (k = 60) have variable outcomes. Beneficial results are more frequent in studies with a high 
risk of bias
Contopoulos‑Ioannidis_2003 Diverse Out of 64 publications of animal studies in highly cited basic science journals, 16 interventions were 
tested in a published clinical trial, 12 of which had positive results
Corpet_2005 Oncology Relative Risks after treatment were discordant for 2 out of 11 compounds between rats and humans, 
and mice and humans
Faggion_2009A Dentistry pocket depth reduction and attachment level gain were similar for animals and humans
Hackam_2006 Diverse Successful translation is not predicted by study methodology, but it is predicted by the presence of 
dose–response gradients in animals
Johnson_2001 Oncology Xenograft models that were available at this stage could not reliably predict the clinical response
Lindl_2005 Diverse The publications resulting from 51 animal ethics approvals were followed. 16 projects were relevant 
to humans and resulted in 63 publications that were cited 1183 times. 97 citations were clinically 
oriented, of which only 4 evidenced an animal‑human correlation. The hypotheses verified in 
animals failed in every respect in humans
Perel_2006 Diverse For 6 interventions, animal and clinical studies were concordant for 3 and discordant for the other 3
Steinberg_1987 Pancreatitis With the same 5 interventions, 81% of animal studies had a positive outcome, and only 7.7% of the 
human studies.
Sultan_2017 Cardiology Most of the human data did not show any effect of cannabidiol, while the animal studies did
Valles_2018 Dentistry Results from animal and human studies are concordant
Voskoglou‑Nomikos_2003 Cancer None of the primary analyses showed a significant correlation
Whiteside_2008 Pain For effective pain treatments, the correlation between human and rat effective doses is good
Yardley_2016 Alcohol abuse Out of 49 animal studies (on 8 drugs), 45 showed positive results. Out of 76 human studies, 56 
showed positive results.
Yen_2014 Dentistry Animal models and human results showed similar bone filling ratios
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Table 4 References on translational success in studies of adverse events and toxicology
Study ID Field of research Summary of findings
Alden_2011 Carcinogenicity Out of 287 registered drugs that were tested in rats and mice for carcinogenicity, results were concordant 
with humans for 146
Allen_1988 Carcinogenicity Correlation of carcinogenic dose between animals and humans ranged from 0.49 to 0.90 depending on 
the analysis
Bailey_2013 Safety All likelihood ratios (LRs) are larger than 1, indicating predictive value of the experiments in dogs. Inverse 
negative LRs (iNLRs) are very small, indicating relatively limited predictive value of negative results in 
dogs for humans. Positive LRs (PLRs) for dogs are large; if toxicity is observed in dogs, it is likely to occur 
also in humans. There is no correlation between positive predictive values (PVVs) and PLRs
Bailey_2014 Safety All LRs are larger than 1, indicating predictive value of the experiments in rats, mice and rabbits. iNLRs are 
very small, indicating relatively limited predictive value of negative results in these species for humans. 
PLRs for these species are large; if toxicity is observed in rats, mice or rabbits, it is likely to occur also in 
humans. Both PLR and iNLR depend on sample size
Bailey_2015 Safety All LRs are larger than 1, indicating predictive value of the animal experiments. iNLRs are very small, indi‑
cating relatively limited predictive value of negative results in animals for humans. PLR for non‑human 
primates (NHPs) is large; if toxicity is observed in NHP, it is likely to occur also in humans
Brown_1983 Teratogenicity Correct positives: 30–97%; correct negatives: 35–80%; animal to human lowest effective dose ratio: 1.8–50
Claude_2007 Adverse events 70% of human adverse events was predicted by animal models. Predictivity is higher for non‑rodents 
than rodents. Predictivity was highest for haematological and cardiovascular, and lowest for cutaneous 
and ophthalmological adverse events
Crouch_1979 Carcinogenicity Data for carcinogenic potency correlated
Davis_1998 QT prolongation Out of 9 noncardiac drugs that show QT prolongation in humans, literature on dog cardiac effects was 
found for 7; 6 showing QT prolongation, 1 showing increased mortality
Ennever_2003 Carcinogenicity Sensitivity appears to be high, but the lifetime rodent bioassay lacks accuracy. Sensitivity decreases if only 
results that are positive in both rats and mice are considered positive. The LRB produces many false 
positives and false negatives
Fletcher_1978 Adverse events Correlations between animal toxicity and human adverse events are considerably more frequent than 
discrepancies. Gastro‑intestinal adverse events show the best correlation
Fourches_2010A Drug‑induced liver injury The concordance of liver effects between rodents and humans (44%) and between non‑rodent species 
and humans (40%) was low
Freireich_1966 Toxic dose Results in preclinical tests correlate remarkably well with results in man
Goodman_1991 Carcinogenicity For 18 out of 20 examined chemicals with sufficient evidence, human and rodent evidence are consistent
Hoffmann_2018 Skin sensitization Overall accuracy in skin sensitization prediction from animal to human was 74%, which decreased to 45% 
when considering five categories of potency
Igarashi_1995 Adverse events Out of 31 pharmacological items tested after systemic administration, 17 showed a significant association 
with any clinical adverse reaction
Litchfield_1961A Adverse events 18 out of the 53 physical signs observed in man were predicted correctly in rats; 29 out of the 53 in dogs
Litchfield_1962 Adverse events Out of the 86 physical signs analysed in animals, 64 accurately reflected occurrence or absence in man
Monticello_2017 Adverse events Excluding subjective adverse events, for rodents, PVV ranged from 0 to 54% and NPV ranged from 69 
to 96%; for dogs, PVV ranged from 0 to 52% and NPV ranged from 76 to 96%; and for monkeys, PVV 
ranged from 0 to 91% and NPV ranged from 70 to 100%
Olson_2000A Adverse events In any species tested, 71% of human adverse events was predicted. Predictivity is higher for non‑rodents 
than rodents. Predictivity was highest for haematological, cardiovascular and gastrointestinal toxicities, 
and lowest for cutaneous toxicities
Schein_1970 Adverse events For the prediction of certain adverse event in humans, administration of highly toxic dose levels to 
animals is needed
Schein_1973a Adverse events For most organ systems, combining dog and monkey data reduces false negatives for prediction of 
human adverse events for anticancer drugs
Schein_1973b Adverse events Correct predictions of anticancer drug‑induced adverse events are accompanied by a high percentage of 
false positives
Schein_1975 Adverse events Results from 13 additional drugs generally overlap with the preceding analysis
Tamaki_2013 Adverse events 37% of adverse drug reactions in humans were predicted from animal studies
VanMeer_2012 Severe adverse reactions Performed animal studies are not sensitive enough to predict post‑marketing serious adverse reactions
Weaver_2003 Adverse events No significant associations were observed between human and guinea pig data
Wilbourn_1986 Carcinogenicity Sensitivity for the predictivity of animals for human carcinogenicity is high (84%), and there is good con‑
sistency between animals and humans in target organs
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Table 5 References on translational success in pharmacokinetics
Study ID Field of research Summary of findings
Akabane_2010A Absolute bioavailability Bioavailability in cynomolgus monkeys is unsuitable for predicting PK in humans
Bachmann_1989 Clearance Predicted values are in the same order of magnitude as actual values
Bachmann_1996A Volume of distribution Human volume of distribution and half‑life values can be predicted from those in rats
Boxenbaum_1982A Clearance It is not possible to reasonably predict human pharmacokinetic parameters from knowledge 
of these parameters in dogs
Caldwell_2004A Clearance There is a reasonable correlation between human and rat clearance and half‑life; and a good 
correlation for volume of distribution, but only 52–65% of drugs show < twofold error. Go/no 
go decisions based on only rat data should be avoided
Campbell_1994A Clearance Predictive accuracy for clearance from rat, dog and monkey is acceptable. The dog is a poorer 
predictor of clearance than the rat
Cao_2006A Oral bioavailability Oral bioavailability does not correlate between rats and humans;  R2 = 0.29 while intestinal 
permeability correlates better;  R2 = 0.70
Cheng_2008 Oral absorption Human intestinal absorption cannot be precisely predicted by a single screening assay
Chiou_1998A Oral bioavailability Oral bioavailability correlates between rats and humans, and to some extent between dogs 
and humans
Chiou_2000a Oral absorption Similar gastrointestinal absorption may be obtained when doses in humans (/kg body weight) 
are 5–7 times lower than in rats
Chiou_2000bA Oral absorption R2 = 0.51–0.90 for oral absorption between dogs and humans; plasma level peak times seem 
to be shorter for dogs.  R2 = 0.95 for oral absorption between rats and humans.
Chiou_2002A Oral absorption Oral absorption correlates well between monkeys and humans:  R2 = 0.97; bioavailability 
correlates to some extent between monkeys and humans:  R2 = 0.50; clearance correlates 
between monkeys and humans:  R2 = 0.82; time to peak concentration was generally similar 
in humans and monkeys
DeBuck_2007A Volume of distribution Predictions of plasma concentrations after oral dosing are reasonable. Prediction of volume 
of distribution improves when accounting for interspecies differences in plasma protein 
binding. 18 out of 19 drugs had a predicted half‑life within twofold of the actual observed 
half‑life
Dong_2011A Volume of distribution For Monoclonal antibodies with non‑linear kinetics, prediction is poor, with up to 6.3‑fold 
differences
Evans_2006 Clearance, distribution volume 
and residence time
Percentages of correct predictions for clearance, distribution volume and residence time 
for rat, dog and monkey varied from 29 to 91%, and the average margin of error from 44 
to 159%. The authors note that the outcomes are different from similar analyses of other 
compound datasets
Fagerholm_1996 Jejunal permeability For passively absorbed compounds (n = 8), the correlation is high;  R2 = 1.0. For passively 
absorbed compounds, rat permeability estimates can be used to predict human oral absorp‑
tion
Fagerholm_2007a Fraction excreted unchanged Out of 25 compounds, 11 had a fraction of 0 excreted unchanged in both humans and rats. 
For 9 out of 14 compounds with renal excretion in rats and humans the major route of elimi‑
nation differed between species. Findings for monkey–human comparisons were roughly 
comparable
Fagerholm_2007b Unbound fraction in plasma The fraction unbound in plasma correlates between rats and humans;  R2 = 0.67. Different 
prediction methods show different accuracies
Goteti_2010A Clearance Two‑species scaling can be useful, but the prediction of clearance from ≥ 3 species is more 
accurate
Grime_2013A Clearance For 19 out of 22 drugs, rat unbound biliary clearance exceeded human clearance by factors 
ranging from 9‑ to 2500‑fold. Human–dog differences in biliary clearance were less dramatic 
than human‑rat differences
He_1998A Oral bioavailability In human and rat there is generally a good correlation for oral bioavailability, in human and 
dog there is no apparent correlation.
Hosea_2009A Clearance Single species scaling is as accurate or more accurate than multiple‑species allometry
Ito_2005A Intrinsic clearance Human clearance is better predicted by modelling based on in vitro microsomal data than on 
animal data
Jolivette_2005A Clearance, volume of distribution Molecular properties may be used to improve extrapolation from animal to human clearance
Jones_2012A Clearance, mean residence time Prediction was within twofold for 5 out of 7 compounds
Jones_2016C Intestinal availability There is little evidence that one animal species is sufficiently predictive of human first‑pass 
metabolism to be used as a stand‑alone model
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Table 5 (continued)
Study ID Field of research Summary of findings
Kalvass_2007A In vivo potency (EC50), clearance In vivo mouse brain half‑lives are almost identical to human half‑lives. In vivo preclinical to 
clinical extrapolations are superior to extrapolations from in vitro tests
Lave_1999 Clearance Human clearance is most accurately predicted from a combination of in vivo animal and 
in vitro animal and human data
Lave_2002 Clearance Predictions based only on in vitro data are at least as accurate as those based on multiple 
species data
Lennernas_2007 Jejunal permeability A rat model can be used to predict oral drug absorption, but not drug metabolism or oral 
bioavailability
Ling_2009 Clearance Human clearance might be accurately predicted from monkey data
Mahmood_1996a Clearance Human clearance can be estimated from animal data, but caution and scientific judgement 
are needed for interpretation
Mahmood_1996bA Clearance, volume of distribution A new approach incorporating brain weight in the model improves prediction of clearance
Mahmood_1996cA Clearance, volume of distribution Three or more species are needed for reliable prediction of clearance, while volume of distri‑
bution is predicted equally well using data from two species or more
Mahmood_1998a Clearance Mean residence time can be predicted reasonably well for man and can be used for prediction 
of half‑life
Mahmood_1998bA Clearance, volume of distribution Caution should be employed when interpreting clearance predictions for renally excreted 
drugs. Predicted volumes (error − 65.6% to 139.4%) and half‑lives (error − 41.8% to 100%) 
were comparable with observed values in man.
Mahmood_1999 Selection of 1st in human dose The half‑life and bodyweight correlate poorly; body weight is not useful as a predictor
Mahmood_2000a Bioavailability All tested approaches predicting human bioavailability from animal data are inaccurate
Mahmood_2000b Protein binding Unbound human clearance cannot be predicted any better than total human clearance from 
animal data
Mahmood_2001 Maximum tolerated dose Maximum tolerated dose can be predicted with reasonable accuracy using interspecies scal‑
ing
Mahmood_2003 Selection of 1st in human dose Animal PK data from a dose not producing adverse events can be used to estimate a suitable 
human starting dose
Mahmood_2004 Clearance More than two species are needed for reliable clearance predictions of protein drugs
Mahmood_2006 Clearance There is no single method for predicting human clearance from animal data for all classes of 
drugs
Mahmood_2009 Clearance Predictions based on at least 3 animal species remain more accurate than one or two‑species 
methods
Mahmood_2012 Clearance, volume of distribution The human clearance of drugs that are excreted in the bile can be predicted with reasonable 
accuracy from animal data. The volume of distribution does not appear to be affected by 
biliary excretion
Mahmood_2013 Concentration–time profiles Human concentration–time profiles of therapeutic proteins can be predicted reasonably 
accurate from animal data
Mahmood_2013 Clearance, volume of distribution Concentration–time profiles are accurately predicted for most time points
Mahmood_2016 Clearance, volume of distribution Human plasma time–concentration profiles, oral clearance and volume of distribution can be 
predicted with reasonable accuracy
McGinnity_2007 Clinical dose, maximum 
concentration & volume of 
distribution
There is a reasonable to good correlation between projected and clinical human dose, 
observed and predicted maximum concentration for a given human dose and predicted 
and observed human volume of distribution
Musther_2014 Oral bioavailability Bioavailability in animals is not quantitatively predictive of bioavailability in humans
Nagilla_2004 Clearance Prospective allometric scaling is a suboptimal technique for estimating human clearance data 
from in vivo preclinical data
Naritomi_2001 Clearance Animal data improve predictions of human clearance from in vitro liver microsomes
Obach_1997 Volume of distribution, clearance Methods for accurate prediction of human PKPD based on animal data do not currently exist, 
but many methods result in adequate predictions
Paine_2011 Clearance The most accurate predictions of human renal clearance are obtained from a direct correlation 
with dog renal clearance. Adding data from rats decreases predictability
Pogessi_2004 Volume of distribution, clearance In most cases, animal‑based predictions are within two or threefold of those observed in 
humans
Rocchetti_2007 Active dose Therapeutically active concentrations of anticancer drugs can be estimated from preclinical 
studies
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translational success rates ranged from 0 to 93%. Binary 
definitions comprise the diagnostic statistics fold error 
(i.e. the percentage of studies/compounds below two-
fold error), percentage of studies/compounds/adverse 
events accurately predicted, positive predictive values 
and negative predictive values. For studies using quan-
titative definitions of translation, translational success 
rates ranged from 0 to 100%. Quantitative definitions 
comprise the diagnostic statistics correlation/regres-
sion  (r2 expressed as a percentage) and meta-analyses 
(percentage overlap of 95% confidence intervals of the 
summary measure). The outcomes of analyses of trans-
lational success could be affected by the choice of defi-
nition, but the range is large either way.
As we included reviews using different units of analy-
ses, we compared the effect of the unit: event (e.g. a spe-
cific adverse event), intervention (mostly drugs) or study 
(or publication) on translational success rates in a box-
plot (Fig. 4). For the 8 studies analysing events, the trans-
lational success rate ranged from 7 to 74%. For the other 
two units of analysis, ranges comprised the full spectrum 
of 0–100% translational success.
We copied the translational success rates from the 
authors where possible, but also included papers 
for which the summary measure of interest was not 
directly given (e.g. manually calculating a correlation 
or a percentage overlap in 95% CI, refer to the meth-
ods for further information). We visually compared the 
Table 5 (continued)
Study ID Field of research Summary of findings
Sanoh_2012 Clearance PXB chimeric mice can be used for at least semi‑quantitative prediction of human clearance 
and half life
Sanoh_2014 Metabolism Human metabolites were sufficiently predicted from the animal data for 10 out of 16 com‑
pounds; predictions were insufficient for 6 out of 16 compounds
Sawada_1985A Clearance, volume of distribution Predictions for human clearance, volume of distribution and half‑life from rat data were suc‑
cessful for most drugs, with marked exceptions
Sawada_1985B Volume of distribution Prediction of human volume of distribution based on animal plasma unbound fraction was 
successful for most drugs
Schneider_1999 Clearance Dog and rat in vivo hepatic drug clearance data appear unrelated with human data
Sietsema_1989 Oral bioavailability Absolute bioavailability does not correlate well between species
Takahashi_2009 Bioavailability The bioavailability in cynomolgus monkeys was low compared to that in humans for most 
drugs tested
Tang_2005 Clearance A new mathematical model based on unbound fractions can improve prediction of human 
clearance from animal data
Tang_2006 Clearance There is no strong evidence that human systemic clearance is more predictable from animal 
data than human oral clearance
Wajima_2002 Clearance Multiple linear regression of animal data generally predicts human clearance better than 
allometric methods
Wajima_2003 Oral clearance The partial least square method based on animal data generally predicts human oral clearance 
better than allometric approaches
Walton_2004 Clearance Average differences in the internal doses between humans and animals were 1.6 for dogs, 3.3 
for rabbits, 5.2 for rats and 13.0 for mice
Wang_2010 Clearance Human clearance can generally be predicted well from animal data with simple allometric 
scaling
Ward_2004a Clearance Generating data in multiple non‑human species does not always result in improved prediction
Ward_2004b Volume of distribution The monkey provides the most accurate PKPD predictions for humans. The allometric expo‑
nent cannot be used as a reliable marker of predictive success
Ward_2005 Clearance The rat is not as accurate a predictor as the monkey, but still affords reasonable human predic‑
tivity
Ward_2005 Oral systemic exposure Liver‑corrected oral exposure was within twofold of human for 30% of compounds for rats, 
and for 48% for dogs. The monkey was the preclinical species most similar to humans
Ward_2008 Clearance Reasonable predictive accuracy of pharmacokinetic parameters in humans can be achieved 
with African green monkeys
Ward_2009 Bioavailability The African green monkey provides similar predictivity for human oral exposure as other 
monkeys
Whiteside_2010 Maximum concentration Rat models for pain predict effective exposure levels in humans. Effective plasma concentra‑
tions also correspond.
Wong_2004 Clearance The chimpanzee serves as a valuable surrogate model for human pharmacokinetics
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percentages calculated by us with those calculated by 
the authors of the included papers in a boxplot (Fig. 5). 
Both categories comprised the full range of 0–100% 
translational success.
We then grouped the included studies into broad 
research categories: toxicology, PKPD and efficacy. 
Translational success rates by category are shown in 
Fig.  6. No clear differences are observed between these 
categories. Differences may still be present between more 
precisely defined medical fields (e.g. cardiovascular dis-
ease, neuroscience, inflammation, oncology), but in-
depth analysis of differences in translational success rates 
between these fields is not possible based on the avail-
able data, as most fields have been analysed only once or 
twice.
We next grouped the included studies by species. 
Translational success rates by species are shown in Fig. 7. 
Several references did not specify the species used, sev-
eral others only presented data from several species 
pooled. Only few studies were available on guinea pigs, 
only one on pigs. No clear differences are observed 
between species.
Our next analysis shows the reported translational 
success rates by study size (i.e. number of included com-
pounds/interventions, studies/experiments, or symp-
toms/events, all referred to as K, Fig. 8). The studies with 
n > 200 are all toxicology studies using a binary definition 
of translation and have been described above.
To test the potential effects of the various search strat-
egies used, we compared the translational success rates 
between studies retrieved via our network, reference 
lists and database searches. Translational success rates 
by source are shown in Fig.  9. No clear differences are 
observed between these sources; all ranges comprise 
translational success rates of 2–99%.
Our last analysis shows the reported translational suc-
cess rates by publication date (Fig.  10). We observe an 
increase of both the numbers of studies and the observed 
range of translational success over time.
Risk of bias and reporting quality
Our analysis of the reporting quality of the included 
references and the risk of bias is summarised in Fig. 11. 
Many details of the review designs were poorly reported, 
resulting in an overall unclear risk of bias for our scoping 
review.
Reporting of the selected PRISMA-items was also 
poor; none of the references described the posting of a 
protocol, the number of people screening the papers, the 
number of people extracting the data, or prespecifying 
the analyses. Specific eligibility criteria were described in 
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Fig. 4 Reported translational success rates (%) by analysis unit
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31 out of the 121 references (26%), limitations by 37 out 
of the 121 references (31%).
Out of the 121 references, 27 contained specific infor-
mation on the funding. Risk of funding bias could work 
in two directions; studies funded by animal rights organi-
zations are expected to find lower than average trans-
lational success rates while those with funding from 
pharmaceutical companies and governmental organiza-
tions may be more inclined to overestimate translational 
success. If we include the affiliations of the authors in our 
risk of bias assessment for the funding, 81 out of the 121 
references had a high risk of funding bias.
Conclusion
General considerations
This systematic scoping review of reviews provides an 
overview of research efforts on translational success 
rates. It shows that the amount of available evidence and 
the overall quality are limited, and that there is high vari-
ability between study types. The published translational 
success rates range from 0 to 100%. The wide range of 
translational success rates observed in our study, and 
the lack of a clear relationship with any of the analysed 
factors, might indicate that translational success is unpre-
dictable; i.e. it might be unclear upfront if the results of 
primary studies will contribute to translational knowl-
edge. However, the risk of bias of the included studies was 
high, and much of the included evidence is older (note 
that this is a review of reviews, the most recent included 
reviews will be based on older data), while newer mod-
els have become available. Therefore, the cumulative evi-
dence of current papers on this topic is insufficient and 
further “umbrella”-studies of translational success rates 
are still warranted.
We included studies on animal-to-human translation. 
We originally defined successful translation as replication 
in a randomized trial in humans of statistically signifi-
cant positive, negative or neutral results for the primary 
study outcome in animal experiments. However, we did 
not define “replication”. When writing the protocol, we 
intended to include studies based on systematic reviews 
[59], animal ethics requests [58] and highly cited animal 
publications [57]. The set of included studies however 
also comprises many correlational and modelling PK 
studies, in line with our adapted definition of transla-
tion: “the quantitative degree of correspondence between 
0
25
50
75
100
dog guinea pig mouse na NHP pig rabbit rat various
species
Tr
an
sl
at
io
n
Fig. 7 Reported translational success rates (%) by species. NA information on species not available
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the results from a trial in humans with results in animal 
experiments”.
We do not see a difference in predictivity between 
toxicology, PKPD and efficacy studies. Before we ran 
the analyses, we expected the toxicology studies to be 
more predictive than the efficacy studies, first, because 
toxicology may reflect more conserved physiological 
mechanisms, second, as toxicology studies are gener-
ally performed in multiple species, and third, as toxicol-
ogy studies are generally performed according to Good 
Laboratory Practice standards, resulting in higher inter-
nal validity of the results.
Search
Scoping searches taught us that a full comprehensive 
search strategy would result in large numbers of retrieved 
references, with limited sensitivity. As the resulting 
amount of work was not manageable within a reasonable 
time frame, we opted to perform a scoping review instead 
of a full systematic review, with an in-depth analysis of a 
subset of the literature.
Our search was thus based on thesaurus (i.e. indexed) 
and title words only, resulting in missing those papers 
only describing translation or predictivity in the abstract 
or the text body while not being indexed for them. We 
supplemented our search with alternative strategies, i.e. 
screening the reference lists, contacting first and last 
authors, and contacting our network, to compensate. We 
retrieved more references via these alternative strategies 
(i.e. 60 + 35 = 95, Fig. 1) than via our searches (i.e. 26, 
Fig.  1), underlining the need for improved indexing of 
this type of studies.
Snowballing via reference lists is not an optimal method 
in this field, first because referencing practices are sub-
optimal (compare e.g. the data and figures from [5, 72, 
73, 77]. Second, many studies focussing on alternatives 
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to animal studies also contain information that quanti-
tatively compares animal and human data (e.g. [78] and 
these relevant studies are difficult to identify from their 
titles.
A limitation of our search is that we did not include 
a term for modelling and scaling studies, as we did not 
have this type of study in mind at the time of designing 
our protocol. These studies may not specify translation or 
prediction in their title, e.g. [79, 80]. While using these 
terms will increase the number of irrelevant hits, to be 
complete, we do recommend adding the terms “mod-
elling”, “scaling”, “correlation” and their synonyms to 
retrieve these papers in future searches for translational 
studies.
A further limitation is that we performed our search 
halfway October 2017, which is rather inherent to the 
systematic approach. Systematic reviews of clinical stud-
ies take on average 67.3  weeks from registered start to 
publication [81]. The alternative supplementary strate-
gies increase the review duration, as screening of refer-
ence lists and contacting authors of the included studies 
could only be finalised after full-text screening had been 
completed and discrepancies between reviewers had 
been resolved.
We are aware that not all available evidence has been 
included. To prevent eternal snowballing and to finish 
this review in a timely manner, we decided to stop retriev-
ing further references from the second-line reference lists 
onwards. During data-extraction, our occasional checks 
of reference lists of the later included papers showed that 
most studies had already been included, indicating that, 
for a scoping review, our data-set can be considered as 
almost complete.
A full systematic review following the methodol-
ogy described in this scoping review would probably 
result in a larger data set. However, we cannot envision 
our alternative search strategies to be biased towards a 
certain outcome. Contacting the authors of the papers 
retrieved by the search is relatively objective and repro-
ducible. The authors’ network should not induce substan-
tial bias either, as the opinions on translational success 
rates between the authors vary. The main outcome of 
this study is the observed range of translational success 
rates. As this comprises all possible values (0–100%) it 
could not change because of more complete sampling 
strategies.
Data quality and risk of bias
Some of the general issues with analysing translational 
failure and success rates have been described before [82]. 
Besides, our analyses are affected by several factors. Fac-
tors generally affecting the quality of scoping reviews 
comprise publication bias, unblinded data selection, 
unblinded extraction, unblinded analysis and statistical 
power. Publication bias is the relative underreporting of 
studies not showing a significant effect in scientific lit-
erature. For the observed range of reported translational 
success rates, from 0 to 100%, we do not consider pub-
lication bias a specific concern. We strove to limit bias 
in the inclusion of data by having two reviewers select 
papers independently. Of note, the observed range of 
translational success was not drastically affected by pub-
lication date or manner of publication retrieval. Data 
extraction and analysis were not performed in a blinded 
manner, but the extractor (CHCL) had no a priori expec-
tations on the results. As data were not quantitatively 
analysed, statistical power is not relevant.
Besides, several factors specifically affect the quality 
of the data included in this work. The first is the prob-
lem with dependency of the data; several authors and 
research groups publish multiple papers on translational 
success rates, often based on (partially) overlapping data 
sets. For example, Schein present an analysis of 25 anti-
cancer drug toxicities in several papers [83–86], each 
paper combining the analysis with other information. 
For our quantitative analyses, we aimed for incorporating 
each dataset only once, but if datasets only overlapped 
partially, they were both included.
The second is that we included several measures for 
translational success, based on different definitions, using 
different diagnostic statistics. We classified the different 
measures into two broad categories, based on the under-
lying definition of translational success, which could be 
binary (yes/no) or continuous (% concordance), and did 
not observe large differences in observed translational 
success rates between these categories. Translational suc-
cess rates were also not affected by unit of measurement 
(event, intervention or study) used in the original review, 
or by who did the calculations (us or the authors of the 
review). However, the percentage overlap in CIs, which 
we used to describe translational success for meta-analy-
ses, is disputable for two reasons. First, the overlap in CIs 
could be fair even if the estimates are quite far apart if 
both estimates are unprecise. We consider the CIs of the 
included studies not to be that large. Second, many scien-
tists argue that the size of the effect is irrelevant as long 
as the direction of the effect is the same. As described in 
our methods, for the included meta-analyses, only one 
set of CIs, from rats and humans, did not overlap [65]. 
The direction of the effect here was opposite, and we 
included it in our analyses as 0% concordance. We pre-
ferred including the percentage overlap over excluding 
the meta-analyses from our review, and excluding this 
paper would not have affected the overall observed range 
of translational success.
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A third factor is that dosing and incidence of events are 
often disregarded [82]. Concerning dosing, differences 
in metabolism, weight, distribution volume etc. result 
in different dosing, and oversimplified approaches for 
dose prediction are common [87]. Concerning incidence, 
known human carcinogens may be tested more exten-
sively in animals than compounds without known human 
toxicity, eventually showing positive results in at least 
one preclinical test. Besides these factors, publication 
bias (i.e. the relative underreporting of primary studies 
with negative and neutral results) can obscure transla-
tional failure rates [13].
Our analysis of risk of bias in the included references 
shows an overall unclear risk of bias, with a high risk of 
funding bias for 81 out of the 122 included references. 
Besides, there was a high risk for underpowered stud-
ies in 30 out of 121 included references. Our analysis of 
the reporting quality of the included studies showed that 
most reviews did not comply with the PRISMA guide-
lines, but this is not unexpected, as most of the included 
references did not claim to be systematic reviews.
Many of the included reviews had drugs as the experi-
mental unit. Most of these did not describe their selec-
tion of the drugs, explicit inclusion and exclusion criteria 
were scarce. One that did transparently describe their 
selection procedure excluded studies with novel targets, 
where predictivity is most needed [88]. This same study 
shows that analysing a subset excluding outliers can 
increase the predictivity of the animal studies.
To conclude, the data presented in this paper have 
severe limitations. They should be considered inconclu-
sive and used for hypothesis-generation only. Besides, 
reliably determining actual translational success rates is 
unmanageable as long as the current status of reporting 
of preclinical research leaves room for improvement [89], 
and non-reproducibility is such a critical issue in both 
animal [1] and human [90] studies.
Implications
While the quantity and quality of the available data is 
limited and further studies are still needed, this review 
provides an at least relatively complete overview of pub-
lished evidence on translational success rates. These 
actual numbers for predictiveness are theoretically more 
informative than qualitative, subjectively determined, 
mechanistic similarities between animal models and 
human pathology. Therefore, for animal studies aimed at 
translation to the human situation, where possible, prob-
abilistic evidence for predictivity should be considered 
besides or even instead of mechanistic evidence.
Of note, animal studies may contribute to success-
ful translation in other manners than direct predic-
tion of the human response; they can for example be 
informative in hypothesis-generation for mechanisms 
underlying disease. We emphasise that this review does 
not provide any information on the usefulness of ani-
mals in fields of animal use that do not directly target 
predictivity for humans.
To ensure validity of the gathered animal and human 
data, it is essential that the execution of the studies is 
of high quality, and that the reporting is complete. 
Complete reports of high-quality studies are needed 
to determine actual translational success rates, and 
to identify factors involved in translational success. 
Knowing the factors involved in translational success 
will benefit both animals and humans.
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